Peptide-based Therapeutic Cancer Vaccine: Current Trends in Clinical Application

Overview

Journal Cell Prolif

Date 2021 Mar 23

PMID 33754407

Citations 70

Authors

Wensi Liu

Haichao Tang

Luanfeng Li

Xiangyi Wang

Zhaojin Yu

Jianping Li

Affiliations

Soon will be listed here.

Abstract

The peptide-based therapeutic cancer vaccines have attracted enormous attention in recent years as one of the effective treatments of tumour immunotherapy. Most of peptide-based vaccines are based on epitope peptides stimulating CD8 T cells or CD4 T helper cells to target tumour-associated antigens (TAAs) or tumour-specific antigens (TSAs). Some adjuvants and nanomaterials have been exploited to optimize the efficiency of immune response of the epitope peptide to improve its clinical application. At present, numerous peptide-based therapeutic cancer vaccines have been developed and achieved significant clinical benefits. Similarly, the combination of peptide-based vaccines and other therapies has demonstrated a superior efficacy in improving anti-cancer activity. We delve deeper into the choices of targets, design and screening of epitope peptides, clinical efficacy and adverse events of peptide-based vaccines, and strategies combination of peptide-based therapeutic cancer vaccines and other therapies. The review will provide a detailed overview and basis for future clinical application of peptide-based therapeutic cancer vaccines.

Citing Articles

Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy.

Delgado-Almenta V, Blaya-Canovas J, Calahorra J, Lopez-Tejada A, Grinan-Lison C, Granados-Principal S Pharmaceutics. 2025; 17(2).

PMID: 40006583 PMC: 11859086. DOI: 10.3390/pharmaceutics17020216.

Dynamic Visualization of Computer-Aided Peptide Design for Cancer Therapeutics.

Hou D, Zhou H, Tang Y, Liu Z, Su L, Guo J Drug Des Devel Ther. 2025; 19:1043-1065.

PMID: 39974609 PMC: 11837852. DOI: 10.2147/DDDT.S497126.

Optimizing the discovery bioanalysis strategy for macrocyclic peptides.

Zhang X, Dale S, Cui Y, Napoli J, Nguyen H, Cai J Anal Bioanal Chem. 2025; .

PMID: 39954031 DOI: 10.1007/s00216-025-05781-8.

Cancer vaccine designed from homologous ferritin-based fusion protein with enhanced DC-T cell crosstalk for durable adaptive immunity against tumors.

Wu J, Liang J, Li S, Lu J, Li Y, Zhang B Bioact Mater. 2025; 46:516-530.

PMID: 39868073 PMC: 11764028. DOI: 10.1016/j.bioactmat.2024.12.029.

Advances in nucleic acid-based cancer vaccines.

Liao H, Liu S J Biomed Sci. 2025; 32(1):10.

PMID: 39833784 PMC: 11748563. DOI: 10.1186/s12929-024-01102-w.

References

Akiyama Y, Komiyama M, Nakamura Y, Iizuka A, Oshita C, Kume A . Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assay. Cancer Immunol Immunother. 2012; 61(12):2311-9. PMC: 11029329. DOI: 10.1007/s00262-012-1298-1. View

Obara W, Hara I, Kato Y, Kato R, Inoue K, Sato F . Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette-Guerin for patients with non-muscle invasive bladder cancer. Cancer Immunol Immunother. 2018; 67(9):1371-1380. PMC: 11028097. DOI: 10.1007/s00262-018-2197-x. View

Narita Y, Arakawa Y, Yamasaki F, Nishikawa R, Aoki T, Kanamori M . A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma. Neuro Oncol. 2018; 21(3):348-359. PMC: 6380422. DOI: 10.1093/neuonc/noy200. View

Fujiwara Y, Okada K, Omori T, Sugimura K, Miyata H, Ohue M . Multiple therapeutic peptide vaccines for patients with advanced gastric cancer. Int J Oncol. 2017; 50(5):1655-1662. DOI: 10.3892/ijo.2017.3955. View

Oji Y, Hashimoto N, Tsuboi A, Murakami Y, Iwai M, Kagawa N . Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide. Int J Cancer. 2016; 139(6):1391-401. PMC: 5089562. DOI: 10.1002/ijc.30182. View

Li X, Wang Y, Wang S, Liang C, Pu G, Chen Y . A strong CD8 T cell-stimulating supramolecular hydrogel. Nanoscale. 2020; 12(3):2111-2117. DOI: 10.1039/c9nr08916k. View

Kanekiyo S, Hazama S, Takenouchi H, Nakajima M, Shindo Y, Matsui H . IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides. Oncol Rep. 2018; 39(5):2385-2392. DOI: 10.3892/or.2018.6288. View

Noguchi M, Matsumoto K, Uemura H, Arai G, Eto M, Naito S . An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy. Clin Cancer Res. 2015; 22(1):54-60. DOI: 10.1158/1078-0432.CCR-15-1265. View

Le D, Jaffee E . Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res. 2012; 72(14):3439-44. PMC: 3399042. DOI: 10.1158/0008-5472.CAN-11-3912. View

10.

Nishida S, Ishikawa T, Egawa S, Koido S, Yanagimoto H, Ishii J . Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study. Cancer Immunol Res. 2018; 6(3):320-331. DOI: 10.1158/2326-6066.CIR-17-0386. View

11.

Mittendorf E, Storrer C, Shriver C, Ponniah S, Peoples G . Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Ann Surg Oncol. 2006; 13(8):1085-98. DOI: 10.1245/ASO.2006.03.069. View

12.

Kushner B, Cheung I, Modak S, Kramer K, Ragupathi G, Cheung N . Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission. Clin Cancer Res. 2014; 20(5):1375-82. PMC: 5592799. DOI: 10.1158/1078-0432.CCR-13-1012. View

13.

Mami-Chouaib F, Echchakir H, Dorothee G, Vergnon I, Chouaib S . Antitumor cytotoxic T-lymphocyte response in human lung carcinoma: identification of a tumor-associated antigen. Immunol Rev. 2002; 188:114-21. DOI: 10.1034/j.1600-065x.2002.18810.x. View

14.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

15.

Lawson D, Lee S, Zhao F, Tarhini A, Margolin K, Ernstoff M . Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After.... J Clin Oncol. 2015; 33(34):4066-76. PMC: 4669592. DOI: 10.1200/JCO.2015.62.0500. View

16.

Sawada A, Inoue M, Kondo O, Yamada-Nakata K, Ishihara T, Kuwae Y . Feasibility of Cancer Immunotherapy with WT1 Peptide Vaccination for Solid and Hematological Malignancies in Children. Pediatr Blood Cancer. 2015; 63(2):234-41. DOI: 10.1002/pbc.25792. View

17.

Gubin M, Artyomov M, Mardis E, Schreiber R . Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest. 2015; 125(9):3413-21. PMC: 4588307. DOI: 10.1172/JCI80008. View

18.

Gerdemann U, Katari U, Christin A, Cruz C, Tripic T, Rousseau A . Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther. 2011; 19(12):2258-68. PMC: 3242656. DOI: 10.1038/mt.2011.167. View

19.

Rampling R, Peoples S, Mulholland P, James A, Al-Salihi O, Twelves C . A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma. Clin Cancer Res. 2016; 22(19):4776-4785. PMC: 5026298. DOI: 10.1158/1078-0432.CCR-16-0506. View

20.

Brown T, Byrd K, Vreeland T, Clifton G, Jackson D, Hale D . Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients. Cancer Med. 2019; 8(10):4678-4687. PMC: 6712444. DOI: 10.1002/cam4.2378. View